| Literature DB >> 16364180 |
James N Baraniuk1, Hilda Maibach.
Abstract
BACKGROUND: Recent consensus statements demonstrate the breadth of the chronic rhinosinusitis (CRS) differential diagnosis. However, the classification and mechanisms of different CRS phenotypes remains problematic.Entities:
Mesh:
Year: 2005 PMID: 16364180 PMCID: PMC1343550 DOI: 10.1186/1465-9921-6-149
Source DB: PubMed Journal: Respir Res ISSN: 1465-9921
Clinical subdivisions of chronic rhinosinusitis based on nasal polyposis and aspirin – sensitivity (mean with 95% CI, or % of group).
| 1st Decision | ||||
| Nasal Polyps | ||||
| 2nd Decision | Nasal Polyps with Aspirin Sensitivity (NPasa) | Nasal Polyps with Other Features (NPother) | CRS without (s) Nasal Polyps (CRSsNP) | Osteomeatal Complex Disease (OMC) |
| Aspirin Sensitivity | 17/17 (100%) (airways) | 0/33 (0%) [<10-9] (airways) | 1/28 (4%) [<10-9] (urticaria) | 1/21 (5%) [<10-9] (urticaria) |
| May CT Scan Grade A | 3.35 (3.02 to 3.69) | 3.10 (2.85 to 3.34) ¶¶ | 2.43 (2.22 to 2.64) §§§ † ¶ | 1 (1 to 1) §§§ |
| Blood Eos > 4% B | 11/17 (65%) | 13/33 (39%) | 9/27 (33%) [0.03] | 4/20 (20%) [0.006] |
| % Males | 4/17 (24%) | 12/33 (36%) | 8/28 (29%) | 3/21 (14%) |
| Age (yr) C | 53.0 (48.1 to 57.9) | 43.7 (39.1 to 48.3) § | 40.5 (35.7 to 45.4) §§ | 46.7 (39.4 to 54.1) |
ANOVA: A = 10-20; B = 0.042; C = 0.031. [p] = Fisher's Exact test vs. NPasa. Two-tailed, unpaired Student's t-tests: § p = 0.02; §§ p = 0.002 and §§§ p < 2 × 10-5 vs. NPasa; ¶ p = 0.005 and ¶¶ p < 10-13 vs. OMC; † p = 0.005 vs. NPother.
Asthma and spirometry in chronic rhinosinusitis subsets (mean, 95% CI; or percentage).
| Nasal Polyps with Aspirin Sensitivity (NPasa) | Nasal Polyps with Other Features (NPother) | CRS without Nasal Polyps (CRSsNP) | Osteomeatal Complex Disease (OMC) | |
| Clinical Asthma | 15/17 (88%) Triad Asthma | 23/32 (72%) | 19/28 (68%) | 14/20 (70%) |
| Spirometry | N = 12 | N = 22 | N = 14 | N = 14 |
| FEV1/FVC (%) A | 64.4% (59.8 to 69.0) | 70.9% (65.3 to 76.5) | 78.0% (72.3 to 83.6) § | 79.8% (73.6 to 86.0) §§ |
| FEV1/FVC<70% A | 9/12 (83%) | 9/22 (41%) [<0.05] | 3/14 (21%) [0.008] | 2/14 (14%) [0.003] |
| FEF25%–75% (%) | 48.4% (35.9 to 60.8) | 59.7% (47.9 to 71.5) | 73.9% (58.0 to 89.7) | 69.5% (55.8 to 83.2) |
| FEF25%–75%<70% B | 10/11 (91%) | 11/20 (55%) [0.04] | 4/14 (29%) [0.002] | 6/14 (43%) [0.02] |
ANOVA: A = 0.005; B = 0.014. [p] = Fisher's Exact test vs. NPasa. Two-tailed, unpaired Student's t-tests: § p = 0.002, and §§ p = 0.0009 vs. NPasa.
Numbers of subjects per group with positive allergy skin tests (%).
| Nasal Polyps with Aspirin Sensitivity (NPasa) | Nasal Polyps with Other Features (NPother) | CRS without (s) Nasal Polyps (CRSsNP) | Osteomeatal Complex Disease (OMC) | |
| Group Sizes (N) | 16 | 31 | 28 | 17 |
| N (%) Positive | 7 (44%) | 22 (71%) {0.03} | 19 (68%) | 7 (41%) |
| Trees | 5 (31%) | 12 (39%) {0.04} | 10 (36%) | 2 (12%) |
| Grasses | 6 (38%) | 10 (32%) | 10 (36%) | 4 (24%) |
| Ragweed | 2 (13%) | 11 (36%) | 8 (29%) | 2 (12%) |
| Weeds | 4 (25%) | 5 (16%) | 7 (25%) | 2 (12%) |
| Mites ( | 6 (38%) | 15 (48%) | 14 (50%) | 5 (29%) |
| Cat | 4 (25%) | 13 (42%) | 9 (32%) | 3 (18%) |
| Dog | 3 (19%) | 6 (20%) | 4 (14%) | 0 (0%) |
| Fungi | 3 (19%) | 6 (20%) | 10 (36%) | 4 (24%) |
| Cockroach | 1 (6%) | 4 (13%) | 5 (18%) | 2 (12%) |
| Persistent § | 6 (38%) | 21 (68%) [0.04] | 17 (61%) | 7 (41%) |
| Subjects with IgE <10 IU/ml but positive skin tests | #1. Trees, grasses, weeds, | #1. Grasses | #1. Trees, | #1. Grasses, ragweed, weed, fungi, cat |
[p] = Fisher's Exact test vs. NPasa; {p} vs. OMC. Df, Dermatophagoides farinae; Dp, D. pternonyssinus; § Persistent was defined as at least 1 positive result to fungi, cat, D. farinae or D. pteronyssinus.
Frequencies of immunoglobulin isotypes below the lower limits of normal.
| Nasal Polyps with Aspirin Sensitivity (NPasa) | Nasal Polyps with Other Features (NPother) | CRS without (s) Nasal Polyps (CRSsNP) | Osteomeatal Complex Disease (OMC) | |
| IgE<10 IU/ml | 4/14 (29%) | 4/24 (17%) | 11/25 (44%) {0.03} | 9/20 (45%) {0.03} |
| IgA | 2/12 (17%) | 2/21 (10%) | 5/18 (28%) | 2/14 (14%) |
| IgM | 1/12 (8%) | 3/21 (14%) | 7/18 (39%) | 3/14 (21%) |
| IgG1 | 4/12 (33%) | 5/21 (24%) | 8/18 (44%) | 5/14 (36%) |
| IgG2 | 2/12 (17%) | 2/21 (10%) | 4/18 (22%) | 2/14 (14%) |
| IgG3 | 3/12 (25%) | 3/21 (14%) | 8/18 (44%) | 3/14 (21%) |
| IgG4 | 1/12 (8%) | 3/21 (14%) | 5/18 (28%) | 3/14 (21%) |
| IgE+IgG1/3 * A | 2/12 (17%) | 1/19 (5%) | 8/18 (44%) {0.007} | 2/14 (14%) |
* IgE <10 IU/ml plus either low IgG1 or IgG3. ANOVA: A = 0.02. {p} = Fisher's Exact test vs. NPother.
Qualitative stratification of clinical disorders and positive allergy skin tests by serum IgE (geometric mean, 95% C.I.).
| IgE | 1.7 (0.8 to 2.9) | 35.1 (28.1 to 43.7) | 277 (212 to 364) |
| Clinical Asthma B | 14/29 (48%) | 23/28 (82%) [0.005] | 24/29 (83%) [0.005] |
| FEV1/FVC ≤ 70% | 5/17 (29%) | 7/18 (39%) | 10/18 (56%) |
| FEF25%–75% ≤ 70% | 7/17 (41%) | 11/17 (65%) | 12/18 (67%) |
| Nasal Polyps | 9/29 (31%) | 15/28 (54%) | 17/29 (59%) [0.02] |
| Eosinophilia > 4% | 8/28 (29%) | 12/28 (43%) | 16/29 (55%) [0.03] |
| N per group | 28 | 26 | 26 |
| + Results/subject | 0.74 (0.10 to 1.30) | 3.5 (1.82 to 5.43) † | 5.08 (3.90 to 6.27) †† |
| Trees C | 3 (11%) | 6 (23%) {0.01} | 15 (58%) [0.0003] |
| Grasses A | 4 (14%) | 8 (31%) | 12 (46%) [0.009] |
| Weeds | 2 (7%) | 7 (27%) [0.047] | 4 (15%) |
| Ragweed C | 0 (0%) | 8 (31%) [0.002] | 12 (46%) [0.00003] |
| Fungi B | 1 (4%) | 5 (19%) {0.049} | 11 (42%) [0.0006] |
| Cat B | 3 (11%) | 7 (27%) | 13 (50%) [0.0002] |
| 1 (4%) | 12 (46%) [0.0002] | 18 (69%) [10-6] | |
| 2 (7%) | 10 (39%) [0.006] {0.03} | 17 (65%) [10-5] | |
| "Persistent" §D | 4 (14%) | 15 (58%) [0.001] {0.01} | 23 (88%) [10-8] |
ANOVA: A = 0.04; B = 0.004; C = 0.0003; D < 0.00003. [p] = Fisher's Exact test vs. IgE<10 IU/ml; {p} vs. IgE>100 IU/ml. † Number of positive allergy skin test results per subject (mean; 95% CI): † p = 0.003 and †† p = 10-7 vs. IgE<10 IU/ml by 2-tailed, unpaired Student's t-test.
Figure 1The number of low isotypes was plotted against the proportion of each group having these deficiencies. Low isotypes (n = 7) were identified in 3 CRSsNP and 1 NPother subject. Fewer nasal polyp subjects had low isotypes compared to the nonpolypoid pair of groups. This was demonstrated by the 95% confidence intervals at the midpoint of these curves (bars with error bars at 20%). Polyp and nonpolyp confidence intervals did not overlap. Most of the subjects had no humoral immune deficits (zero low isotypes, not depicted).
Factor analysis for the entire CRS population. The variables that predicted CRS in the most similar fashion were grouped together as Factors. Factors 1 (persistent dust mite) and 3 (seasonal pollens) implicated allergic rhinitis mechanisms. Factor 2 related asthma with polyposis. Independent factors were eosinophilia, aspirin sensitivity and low immunoglobulins.
| Factors | Variables | Loading factors | Explained variance | Eigenvalue |
| Factor 1 | Positive dust mite skin test | 0.93 | 29% | 3.5 |
| Factor 2 | FEV1/FVC ratio (continuous range) | -0.93 | 26% | 3.2 |
| Factor 3 | Positive skin test results to weeds | 0.91 | 15% | 1.6 |
| Factor 4 | Blood eosinophils > 4% (qualitative) | 0.92 | 12% | 0.9 |
| Factor 5 | Aspirin sensitivity | 0.90 | 10% | 0.8 |
| Factor 6 | Any immunoglobulin < lower limits of normal | 0.70 | 8% | 0.6 |
Proposed algorithm for the classification of chronic rhinosinusitis. The numbers of subjects in each category and for each variable were extrapolated to a sample size of 100 based on the current data. The 4 categories were generated from the 3rd Decision. The numbers of projected subjects per category (and % per category) were shown in each column. The far right column gives the sum for each variable per 100 CRS subjects.
| 1st Decision: Polyps | CRS with Nasal Polyps | CRS without Nasal Polyps | N | ||
| 50.5 | |||||
| 2nd Decision: Aspirin sensitivity | Nasal Polyps with Aspirin Sensitivity (NPasa) | Nasal Polyps with Other Features (NPother) | CRS without (s) Nasal Polyps (CRSsNP) | Osteomeatal Complex Disease (OMC) | |
| 17.1 (airways) | 0 | 3.6 (urticaria) | 4.8 (urticaria) | 25.5 | |
| 3rd Decision: Sinus mucosal thickening | 17.1 | 33.3 | 28.3 | 21.2 (normal sinuses) | 78.7 |
| 4th Decision: | 12.8 (75%) | 13.7 (41%) | 5.9 (21%) | 3.0 (14%) | 35.4 |
| 5th Decision: | 11.1 (65%) | 13.1 (39%) | 9.4 (33%) | 4.0 (19%) | 37.6 |
| 6th Decision: | 4.9 (29%) | 5.5 (17%) | 12.5 (44%) | 9.5 (45%) | 32.4 |
| 7th Decision: | 7.5 (44%) | 23.6 (71%) | 19.2 (68%) | 8.7 (41%) | 59.0 |
| Total per Group | 17.1 (100%) | 33.3 (100%) | 28.3 (100%) | 21.2 (100%) | 99.9 |